[Antibody therapy for acute lymphoblastic leukemia]

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed or refractory acute lymphoblastic leukemia (ALL) presents significant treatment challenges.
• Novel antibody therapies offer new treatment avenues for ALL patients.
• In 2018, Japan approved inotuzumab ozogamicin (InO) and blinatumomab for ALL.

Purpose of the Study:

• To review the efficacy and safety of inotuzumab ozogamicin and blinatumomab in treating relapsed or refractory acute lymphoblastic leukemia.
• To compare these novel antibody therapies with conventional chemotherapy.
• To discuss the role of allogeneic hematopoietic stem cell transplantation in maintaining long-term remission.

Main Methods:

• Review of clinical trial data and treatment guidelines for inotuzumab ozogamicin and blinatumomab.
• Analysis of remission rates, minimal residual disease negativity, and adverse events.
• Evaluation of post-treatment management strategies, including stem cell transplantation.

Main Results:

• Inotuzumab ozogamicin demonstrated a remission rate of approximately 75%, with an increased risk of sinusoidal obstruction syndrome post-transplantation.
• Blinatumomab achieved remission rates of 45-70%, requiring management of cytokine release syndrome in some cases.
• Both therapies show higher remission and minimal residual disease negativity rates compared to conventional chemotherapy.

Conclusions:

• Inotuzumab ozogamicin and blinatumomab represent significant advancements in treating relapsed/refractory ALL.
• Long-term remission maintenance remains a critical challenge for these therapies.
• Allogeneic hematopoietic stem cell transplantation should be considered as a standard approach to consolidate remission.